USPTO Examiner KOMATSU LI N - Art Unit 1658

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18960248INSECT NEUROPEPTIDES 9November 2024November 2025Allow1121YesNo
18812797GLP-1/GIP DUAL AGONISTSAugust 2024August 2025Allow1121NoNo
18650574ANTI-AGING STURGEON ROE TETRAPEPTIDE AND PREPARATION METHOD AND APPLICATION THEREOFApril 2024April 2025Allow1111YesNo
18640676METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTSApril 2024October 2025Abandon1811NoNo
18604451DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASEMarch 2024December 2025Abandon2211NoNo
18602026AGENTS AND METHODS FOR TREATING CBP-DEPENDENT CANCERSMarch 2024October 2025Allow1921NoNo
18598577METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTSMarch 2024October 2025Abandon1911NoNo
18596026THERAPEUTICS DIRECTED AGAINST CORONAVIRUSMarch 2024December 2025Abandon2221NoNo
18591918ACTIVIN RECEPTOR TYPE IIB VARIANTS AND USES THEREOFFebruary 2024May 2025Allow1501YesNo
18435934NOVEL HYBRID ACTRIIB LIGAND TRAP PROTEINS FOR TREATING MUSCLE WASTING DISEASESFebruary 2024October 2025Abandon2011NoNo
18413417AQUEOUS PEPTIDE PROGRAMMING OF THE VINYLIDENE FLUORIDE FERROELECTRIC PHASEJanuary 2024January 2026Allow2421YesNo
18413390TOPICAL COMPOSITIONS CONTAINING N-ACYL DIPEPTIDE DERIVATIVES AND GLYCOLIC ACIDJanuary 2024October 2025Abandon2121NoNo
18543288CROSSLINKED HYALURONIC ACID-COLLAGEN GELS FOR IMPROVING TISSUE GRAFT VIABILITY AND SOFT TISSUE AUGMENTATIONDecember 2023October 2025Abandon2211NoNo
18568888SURFACE LAYER PROTEIN A (SLPA) AS A THERAPEUTIC AGENT FOR THE TREATMENT OF INFLAMMATORY DISEASESDecember 2023May 2024Allow500YesNo
18527616HYALURONIC ACID-COLLAGEN MATRICES FOR DERMAL FILLING AND VOLUMIZING APPLICATIONSDecember 2023October 2025Abandon2311NoNo
18385946CNP COMPOUNDSNovember 2023May 2024Allow601YesNo
18492076INSECT NEUROPEPTIDES 9October 2023October 2024Allow1221YesNo
18491957INSECT NEUROPEPTIDES 1October 2023February 2025Allow1621YesNo
18473627BROWN FAT-SELECTIVE ADIPOKINESSeptember 2023April 2025Allow1821YesNo
18460215MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSISSeptember 2023August 2025Allow2301YesNo
18457482GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS AND USES THEREOFAugust 2023May 2024Allow800YesNo
18450524RAGE PROTEINS FOR THE TREATMENT OF FIBROSIS AND DNA DAMAGE MEDIATED DISEASESAugust 2023June 2025Abandon2211YesNo
18227782COMPOUND WITH ANALGESIC EFFECT FOR USE IN PREVENTION AND TREATMENT OF PAINJuly 2023July 2024Allow1201YesNo
18360773COMPOSITION FOR IMPROVING MILD COGNITIVE IMPAIRMENT AND METHOD FOR IMPROVING MILD COGNITIVE IMPAIRMENTJuly 2023November 2024Abandon1610NoNo
18348878PREPARING METHOD OF HIGHLY FUNCTIONAL PEPTIDE DERIVED FROM KERATINOCYTE PROTEINJuly 2023September 2024Abandon1410YesNo
18330109GROWTH PROMOTING PEPTIDES, AND USES THEREOFJune 2023August 2024Abandon1401NoNo
18203184ERYTHROPOIETIN AND ANALOGS FOR VETERINARY USEMay 2023August 2024Abandon1401NoNo
18318343COMPOSITIONS COMPRISING PCSK9-BINDING MOLECULES AND METHODS OF USEMay 2023May 2025Allow2411YesNo
18144630Compositions Containing a Pharmacophore with Selectivity to Diseased Tissue and Methods of Making SameMay 2023July 2025Abandon2621YesNo
18301761THERAPEUTICS DIRECTED AGAINST CORONAVIRUSApril 2023January 2024Allow901YesNo
18180002METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTSMarch 2023September 2024Abandon1911NoNo
18118113Skin Compositions and UsesMarch 2023June 2025Abandon2721NoNo
18174751CD71 BINDING FIBRONECTIN TYPE III DOMAINSFebruary 2023November 2025Allow3221YesNo
18112554METHOD FOR ALLEVIATING DEPRESSION USING TNFAIP3-INTERACTING PROTEIN (TNIP) 1February 2023September 2025Abandon3131NoNo
18169097ANTI-ANGIOGENIC AGENT AND METHODS OF USING SUCH AGENTFebruary 2023July 2025Allow2901YesNo
18160787ACTIVIN RECEPTOR TYPE IIB VARIANTS AND USES THEREOFJanuary 2023November 2023Allow1001YesNo
18157307METHODS FOR PREVENTING AND TREATING INTRA-ABDOMINAL CANDIDIASISJanuary 2023January 2025Abandon2411NoNo
18157293CYSTEINE PROTEASE INHIBITORS AND METHODS OF USE THEREOFJanuary 2023May 2024Allow1611YesNo
18002625VASOPRESSIN-2 RECEPTOR ANTAGONIST PEPTIDES AND USES THEREOFDecember 2022December 2025Allow3601YesNo
18061699HISTATIN FOR CORNEAL WOUND HEALING AND OCULAR SURFACE DISEASEDecember 2022December 2024Abandon2411YesNo
17927623COMPOSITION FOR NEUTRALIZING CORONAVIRUSNovember 2022March 2026Abandon3901NoNo
18054587BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSINNovember 2022September 2024Abandon2201YesNo
18053965PEPTIDE FOR TREATING SEPSIS DERIVED FROM RV3364C PROTEIN OF MYCOBACTERIUM TUBERCULOSISNovember 2022April 2024Allow1731YesNo
17981595SELF-ASSEMBLING ANTIVIRAL PRODRUGSNovember 2022January 2024Allow1511YesNo
18050659DUAL AMYLIN AND CALCITONIN RECEPTOR AGONISTS AND USES THEREOFOctober 2022March 2025Allow2901YesNo
18050604DUAL AMYLIN AND CALCITONIN RECEPTOR AGONISTS AND USES THEREOFOctober 2022March 2025Allow2801YesNo
17921508FUSION POLYPEPTIDES FOR TARGET PEPTIDE PRODUCTIONOctober 2022July 2025Allow3201YesNo
17919940PROTEOLYTICALLY STABLE U1-AGATOXIN-TA1B VARIANT POLYPEPTIDES FOR PEST CONTROLOctober 2022February 2026Allow3911YesNo
17937203CAS9 VARIANTS AND USES THEREOFSeptember 2022November 2025Allow3811YesNo
17908853ANTIBACTERIAL PROTEIN HAVING LYTIC ACTIVITY TO BACILLUS GENUS AND METHOD FOR PREPARING THE SAMESeptember 2022June 2025Allow3300YesNo
17823128HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOFAugust 2022January 2026Abandon4001NoNo
17898470NANO SMALL PEPTIDE AND ITS USE IN PREPARATION OF DRUGS FOR TREATING AND PREVENTING FUNDUS VASCULAR DISEASESAugust 2022July 2023Allow1101YesNo
17904142USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS FOR TREATING TP53-MUTATED ACUTE MYELOID LEUKEMIAAugust 2022March 2026Abandon4301NoNo
17818118PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLAMMATORY CYTOKINESAugust 2022March 2026Abandon4351YesNo
17759613POLYPEPTIDES HAVING IMPROVED PROPERTIESJuly 2022February 2026Allow4201YesNo
17864486USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTIONJuly 2022August 2024Abandon2521NoNo
17851339STABILIZED PEPTIDE COMPOSITIONJune 2022September 2025Allow3801YesNo
17784589DEBARYOMYCES SPECIES AS AN INDICATOR OF NON-HEALING ULCERS IN CROHN'S DISEASEJune 2022November 2025Allow4111YesNo
17783822Improved Cell-Permeable Nuclear Import Inhibitor Synthetic Peptide for Inhibition of Cytokine Storm or Inflammatory Disease and Use ThereofJune 2022December 2025Abandon4201NoNo
17757104PHARMACEUTICAL COMPOSITION COMPRISING PEPTIDE THAT INHIBITS INTERACTION OF P53 AND FOXO4June 2022December 2025Abandon4201NoNo
17782610OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOMEJune 2022July 2025Allow3801YesNo
17756721ECHINOCANDIN ANALOGUES AND PREPARATION METHOD THEREFORJune 2022April 2025Allow3521YesNo
17747788COMPOSITIONS AND METHODS OF USING ISLET NEOGENESIS PEPTIDES AND ANALOGS THEREOFMay 2022June 2024Abandon2521NoNo
17741692POLYPEPTIDE, PHOTORESIST COMPOSITION INCLUDING THE SAME, AND METHOD OF FORMING PATTERN USING THE SAMEMay 2022October 2024Allow2931YesNo
17740202PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTSMay 2022November 2023Abandon1801NoNo
17737471CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLSMay 2022September 2025Abandon4031YesYes
17734775BROAD SPECTRUM INHIBITORS OF CRISPR-CAS9May 2022November 2025Abandon4301NoNo
17727579PTD-SMAD7 THERAPEUTICSApril 2022October 2023Abandon1801NoNo
17709731ANTI-RNA VIRAL PHARMACEUTICAL COMBINATION THERAPY WITH APROTININ + anti-RNA DRUGMarch 2022October 2023Abandon1921YesNo
17765342Muscle Tissue-Regenerating AgentMarch 2022April 2025Abandon3601NoNo
17639929Use of Cobra neurotoxin polypeptide molecule in the treatment of nephropathy proteinuriaMarch 2022July 2025Abandon4101NoNo
17640367NOVEL MICROPEPTIDE HMMW AND APPLICATION THEREOFMarch 2022October 2025Allow4421YesNo
17653643METHOD FOR CONTROLLING PROTEIN DIMERIZATION USING AN INTRAMOLECULAR TO INTERMOLECULAR CONFORMATIONAL SWITCHMarch 2022February 2026Allow4711YesNo
17682277Novel Hybrid ActRIIB Ligand Trap Proteins for Treating Muscle Wasting DiseasesFebruary 2022November 2023Allow2011YesNo
17665179HIGHLY POTENT ACID ALPHA-GLUCOSIDASE WITH ENHANCED CARBOHYDRATESFebruary 2022October 2022Allow911YesNo
17586774PEPTIDE FOR COMPLEXING ZINC ION, COMPLEX THEREOF AND USE THEREFORJanuary 2022February 2025Allow3611YesNo
17629999COMPOSITIONS AND METHODS FOR PREPARING FACTOR XA AND DERIVATIVESJanuary 2022April 2025Allow3901YesNo
17579455THERAPEUTICS DIRECTED AGAINST CORONAVIRUSJanuary 2022August 2023Abandon1921YesNo
17627359ACETYLCHOLINE MODULATION OF IMMUNE FUNCTIONJanuary 2022December 2023Abandon2301NoNo
17574865ANTI-INFLAMMATORY PEPTIDES, AND USES THEREOFJanuary 2022May 2023Allow1601YesNo
17624672Modified BCL9 Mimetic PeptidesJanuary 2022October 2025Allow4521YesNo
17566368METHOD FOR DECREASING IMMUNOGENICITY OF PROTEIN AND PEPTIDEDecember 2021December 2023Abandon2411YesNo
17621807PEPTIDE ACETALS FOR STABILISING ENZYMESDecember 2021March 2025Allow3911YesNo
17619334METHODS FOR PROTEIN PURIFICATIONDecember 2021November 2025Abandon4711YesNo
17618117DE NOVO DESIGN OF PHOSPHORYLATION INDUCIBLE PROTEIN SWITCHES (PHOSPHO-SWITCHES)December 2021June 2025Abandon4201NoNo
17546739PREPARING METHOD OF HIGHLY FUNCTIONAL PEPTIDE DERIVED FROM KERATINOCYTE PROTEINDecember 2021December 2023Abandon2421NoNo
17541145Compositions and Formulations and Methods of Production and Use ThereofDecember 2021June 2024Abandon3021YesNo
17538924OCULAR DELIVERY OF CELL PERMEANT THERAPEUTICS FOR THE TREATMENT OF RETINAL EDEMANovember 2021November 2023Allow2311YesNo
17536296AGENTS AND METHODS FOR TREATING CBP-DEPENDENT CANCERSNovember 2021December 2023Allow2421YesNo
17535451TUMOR-SPECIFIC CLEAVABLE LINKERSNovember 2021January 2025Allow3812YesNo
17532978RECOMBINANT COLLAGEN AND ELASTIN MOLECULES AND USES THEREOFNovember 2021August 2024Abandon3321NoNo
17532597METHODS AND COMPOSITIONS COMPRISING A C-TERMINAL BAX PEPTIDENovember 2021March 2025Abandon3931YesNo
17454931ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCERNovember 2021November 2023Allow2421YesNo
17609818PROTEIN INHIBITORS OF CLOSTRIDIUM DIFFICILE TOXIN BNovember 2021August 2024Allow3311YesNo
17512550Antithrombin-III Treatment of Traumatic Brain InjuryOctober 2021September 2023Abandon2201NoNo
17450613THERAPEUTIC METHOD OF TREATMENT FOR INHIBITING TUMOR DEVELOPMENT USING TAMM-HORSFALL GLYCOPROTEIN (THP) AS IMMUNOSTIMULATING DRUG AND COMPOSITIONSOctober 2021March 2023Allow1801NoNo
17493598RECOMBINANT ELASTIN AND PRODUCTION THEREOFOctober 2021November 2024Allow3831YesNo
17600468SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDESSeptember 2021April 2025Allow4211YesNo
17490156WOUND HEALING THERAPEUTIC HYDROGELSSeptember 2021July 2025Abandon4631YesNo
17599625Reagents and Assays using Modified Integrin DomainsSeptember 2021December 2024Allow3911YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KOMATSU, LI N.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
6
(85.7%)
Examiner Reversed
1
(14.3%)
Reversal Percentile
25.6%
Lower than average

What This Means

With a 14.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
37
Allowed After Appeal Filing
6
(16.2%)
Not Allowed After Appeal Filing
31
(83.8%)
Filing Benefit Percentile
18.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner KOMATSU, LI N - Prosecution Strategy Guide

Executive Summary

Examiner KOMATSU, LI N works in Art Unit 1658 and has examined 378 patent applications in our dataset. With an allowance rate of 51.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner KOMATSU, LI N's allowance rate of 51.3% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by KOMATSU, LI N receive 1.95 office actions before reaching final disposition. This places the examiner in the 48% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by KOMATSU, LI N is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +68.8% benefit to allowance rate for applications examined by KOMATSU, LI N. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.0% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 27.7% of cases where such amendments are filed. This entry rate is in the 39% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 53.3% of appeals filed. This is in the 24% percentile among all examiners. Of these withdrawals, 25.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 63.9% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 55% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.1% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.